6345-43-3|Dimethyl pyrimidine-4,6-dicarboxylate| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 6345-43-3 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 6345-43-3 ]

CAS No. :	6345-43-3
Formula :	C₈H₈N₂O₄
M.W :	196.16
SMILES Code :	O=C(C1=NC=NC(C(OC)=O)=C1)OC
MDL No. :	MFCD05864412
InChI Key :	AJTJKDWVSIIOIR-UHFFFAOYSA-N
Pubchem ID :	239362

Safety of [ 6345-43-3 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 6345-43-3 ] Show Less

Physicochemical Properties

Num. heavy atoms	14
Num. arom. heavy atoms	6
Fraction Csp3	0.25
Num. rotatable bonds	4
Num. H-bond acceptors	6.0
Num. H-bond donors	0.0
Molar Refractivity	44.59
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	78.38 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.62
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	0.58
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	0.05
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-0.43
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	0.6
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	0.48

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-1.47
Solubility	6.57 mg/ml ; 0.0335 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.8
Solubility	3.12 mg/ml ; 0.0159 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-1.81
Solubility	3.04 mg/ml ; 0.0155 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	No
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-7.08 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.93

Application In Synthesis of [ 6345-43-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 6345-43-3 ]

[ 6345-43-3 ] Synthesis Path-Downstream 1~35

2
[ 929-59-9 ]
[ 6345-43-3 ]
6,9-dioxa-3,12,15,17-tetraazabicyclo[12.3.1]octadeca-1⁽¹⁸⁾,14,16-triene-2,13-dione [ No CAS ]
6,9,23,26-tetraoxa-3,12,15,17,20,29,32,34-octaazatricyclo[29.3.1.1^14,18]hexatriaconta-1⁽³⁵⁾,14,16,18⁽³⁶⁾,31,33-hexaene-2,13,19,30-tetraone [ No CAS ]

References: [1]Helvetica Chimica Acta,2004,vol. 87,p. 156 - 166.

3
[ 6345-43-3 ]
[ 10406-25-4 ]
C₁₅H₁₂N₄O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
48%	In N,N-dimethyl-formamide; at 60℃;	Example 5; Step A; 4-Cyanolbenzylamine (1.1 g, 8.33 mmol), 4,6-pyrimidine dicarboxylic acid methyl ester (1.77 g, 8.33 mmol) were dissolved in N,N-dimethylformamide (20 mL). The reaction was stirred 60 C. overnight and concentrated. The brown solid was purification with ethyl acetate and hexane (gradient) to give product as light brown solid (1.18 g, 48% yield).

References: [1]Patent: US2008/21024,2008,A1 .Location in patent: Page/Page column 71-72.

4
[ 6345-43-3 ]
[ 140-75-0 ]
C₁₄H₁₂FN₃O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In N,N-dimethyl-formamide; at 60℃; for 24h;	Preparative Example 13; Step A; A solution of commercially available <strong>[6345-43-3]pyrimidine-4,6-dicarboxylic acid dimethyl ester</strong> (1.61 g) and 4-fluorobenzylamine (1.23 g) in DMF (30 mL) was stirred at 60 C. for 24 h. The solvent was evaporated to dryness, the residue dissolved in THF/H2O 1:1 (10 mL) and LiOH H2O (314 mg) was added. The resulting mixture was stirred at rt for 2 h and H2O (50 mL) was added. The reaction mixture was extracted with DCM and acidified with concentrated HCl. The formed precipitate was filtered off and washed with H2O to afford the title compound (1.147 g; 51%). [MH]+=276.

References: [1]Patent: US2008/21024,2008,A1 .Location in patent: Page/Page column 81.

5
[ 6345-43-3 ]
[ 100-46-9 ]
methyl-6-benzylcarbamoylpyrimidine-4-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
36%	In DMF (N,N-dimethyl-formamide); at 50℃; for 4h;	2.55 g (0.01299 mol) of the resulting compound <strong>[6345-43-3]dimethyl pyrimidine-4,6-dicarboxylate</strong> were dissolved in 100 ml of dimethylformamide (DMF), after which 1.42 ml (0.01299 mol) of benzylamine were added and the mixture was heated to 50C. After 4 hours, the solution is concentrated under reduced pressure. The residue is chromatographed through a 500 ml silica gel column using heptane/ethyl acetate (1:1). Fractions containing the compound methyl-6-benzylcarbamoylpyrimidine-4-carboxylate were concentrated. Yield: 1.268 g (36%) MS (ES +): m/e = 272.20

References: [1]Patent: US2003/229103,2003,A1 .Location in patent: Page 9.

6
[ 67-56-1 ]
[ 16490-02-1 ]
[ 6345-43-3 ]

Yield	Reaction Conditions	Operation in experiment
94.4%	With hydrogenchloride; In water; at 65℃; for 3h;Heating / reflux;	10g (0.059 mol) of pyrimidine-4,6-dicarboxylic acid were suspended in 1.4 l of methanol, after which 10.93 ml (0.356 mol) of concentrated hydrochloric acid were added and the mixture was stirred under reflux (65C) for 3 hours (h). The reaction mixture was concentrated under reduced pressure after which the residue was taken up once again in methanol; the mixture was filtered and the resulting solution was concentrated.[0121] Yield 11.02 g (94.4%) MS (ES +): m/e = 197.20
79%	With thionyl chloride; at 0℃; for 5h;Inert atmosphere; Reflux;	SOCl2 (4.76 g, 4 mmol) was added to a solution of pyrimidine-4, 6-dicarboxylic acid (3.40 g, 2 mmol) in MeOH (250 mL) at 0C. The mixture was heated under reflux and stirred for 5 h. After cooling to room temperature, the mixture was concentrated in vacuo. The residue was diluted with saturated aqueous NaHC03 (100 mL), and extracted with EtOAc (100 mL>
	With sulfuric acid; for 24h;Reflux;	Dimethyl pyrimidine-4,6-dicalpharboxylalphate (llalpha)To a heated solution (75C) of 4,6-dimethylpyrimidine (846 mg, 8.00 mmol) and NaOH (211 mg, 5.28 mmol) in water (3 mL) was added a solution OfKMnO4 (5.28 g in 25 mL water) overl5 min. The resulting mixture was stirred at 80C for 3 hrs. The hot solution was filtered hot and manganese dioxide washed with hot water (8 mL). The filtrate and washings were concentrated to 5 mL and acidified with cone. HCl to pH 2-3. After cooling, the precipitation was collected, yielding 591 mg of crude pyridine-4,6-dicarboxylic acid. The diacid was then dissolved in MeOH (15 mL) and cone. H2SO4 (1.5 mL) was added dropwise carefully. The mixture was refluxed for 24 hrs, cooled to room temperature and concentrated in vacuo. The resultant oily residue was neutralised with sat. NaHCO3 and extracted with EtOAc (3 x 30 mL). The combined organic extracts were washed with H2O (50 mL) and brine (5OmL), dried over Na2SO4, filtered and concentrated. The product was then purified by column chromatography (petroleum ether 40-60 : EtOAc 5 : 5 to 3 :7) yielding 311 mg (20%) of 11 a as a white solid.

References: [1]Patent: US2003/229103,2003,A1 .Location in patent: Page 9.
[2]Patent: WO2019/99977,2019,A2 .Location in patent: Paragraph 00191; 00362; 00363.
[3]Journal of Medicinal Chemistry,2008,vol. 51,p. 7053 - 7056.
[4]Patent: WO2010/43866,2010,A2 .Location in patent: Page/Page column 77.
[5]Journal of Medicinal Chemistry,2017,vol. 60,p. 307 - 321.

7
[ 3731-53-1 ]
[ 6345-43-3 ]
[ 691003-11-9 ]

References: [1]Patent: WO2004/41788,2004,A1 .Location in patent: Page/Page column 48-49.

8
[ 5071-96-5 ]
[ 6345-43-3 ]
6-(3-methoxy-benzylcarbamoyl)-pyrimidine-4-carboxylic acid methyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In N,N-dimethyl-formamide; at 80℃; for 18h;	A solution of commercially available <strong>[6345-43-3]pyrimidine-4,6-dicarboxylic acid dimethyl ester</strong> (1.96 g) and commercially available 3-methoxy-benzylamine (1.38 mL) in dry N,N-dimethylformamide (10 mL) was placed in a preheated oil bath (80 C.). After stirring at this temperature for 18 h the mixture was concentrated and flash filtered (silica, cyclohexane/ethyl acetate). The obtained material was suspended in dry tetrahydrofurane (10 mL) and treated with a solution of lithium hydroxide (642 mg) in water (15 mL). The resulting mixture was stirred at room temperature for 16½ h, diluted with water (35 mL), washed with dichloromethane (3×50 mL) and acidified by addition of a 1M aqueous solution of hydrochloric acid (20 mL). The formed precipitate was isolated by suction, washed with water (2×50 mL) again suspended/dissolved in water (200 mL) and ultrasonificated for 5 min. The remaining precipitate was isolated by suction and dried under reduced pressure to afford the title compound (700 mg; 24%). [MH]+=288.
	In N,N-dimethyl-formamide; at 80℃; for 18h;	Preparative Example 202; Step A; A solution of commercially available <strong>[6345-43-3]pyrimidine-4,6-dicarboxylic acid dimethyl ester</strong> (1.96 g) and commercially available 3-methoxy-benzylamine (1.38 mL) in dry N,N-dimethylformamide (10 mL) was placed in a preheated oil bath (80 C.). After stirring at this temperature for 18 h the mixture was concentrated and flash filtered (silica, cyclohexane/ethyl acetate). The obtained material was suspended in dry tetrahydrofuran (10 mL) and treated with a solution of lithium hydroxide (642 mg) in water (15 mL). The resulting mixture was stirred at room temperature for 16½ h, diluted with water (35 mL), washed with dichloromethane (3×50 mL) and acidified by addition of a 1M aqueous solution of hydrochloric acid (20 mL). The formed precipitate was isolated by suction, washed with water (2×50 mL) again suspended/dissolved in water (200 mL) and ultrasonificated for 5 min. The remaining precipitate was isolated by suction and dried under reduced pressure to afford the title compound (700 mg; 24%). [MH]+288.

References: [1]Journal of Medicinal Chemistry,2017,vol. 60,p. 307 - 321.
[2]Patent: WO2004/41788,2004,A1 .Location in patent: Page/Page column 46.
[3]Patent: US2006/173183,2006,A1 .Location in patent: Page/Page column 127.
[4]Patent: US2007/155739,2007,A1 .Location in patent: Page/Page column 38-39.

9
[ 6345-43-3 ]
(2,3-dihydro-1-benzofuran-5-yl)methanamine [ No CAS ]
[ 691003-13-1 ]

References: [1]Patent: WO2004/41788,2004,A1 .Location in patent: Page/Page column 50.

10
[ 261951-68-2 ]
[ 6345-43-3 ]
methyl 6-((4-fluoro-3-methylbenzyl)carbamoyl)pyrimidine-4-carboxylate [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2017,vol. 60,p. 307 - 321.
[2]Patent: WO2004/41788,2004,A1 .Location in patent: Page/Page column 44.

11
[ 6345-43-3 ]
[ 612088-38-7 ]

Yield	Reaction Conditions	Operation in experiment
Ca. 100%	With water; sodium hydroxide; In methanol; at 0 - 20℃; for 2h;	Sodium hydroxide (632 mg, 15.8 mmol) was added to a solution of compound 81-1 (3.10 g, 15.8 mmol) in MeOH (60 mL) and H20 (6 mL) at 0C. The resulting mixture was stirred for 2 h at room temperature, then acidified with 1M HC1 aqueous to pH of 3. The mixture was concentrated to dryness. The residue was azeotroped two times with THF (50 mL portions) to afford crude compound 81-2 (3.30 g, -100% yield), which was used for next step without further purification.
86%	With methanol; sodium hydroxide; at 20℃; for 1h;Inert atmosphere;	To a 100 ml round bottom flask containing a stir bar is added commercially available pyrimidine-4,6- dicarboxylic acid dimethyl ester (19) (obtained from Aldrich). To the solid was added a solution comprising 0.2 grams of sodium hydroxide dissolved in 10 ml anhydrous methanol and mixture stirred at room temperature under a nitrogen atmosphere for 1 hour. To the reaction mixture was then added 1.2 ml of a solution comprising 4 M hydrochloric acid in dioxane and mixture stirred for 10 minutes. To the reaction mixture was then added ~2 grams of silica gel (Si02), and the volatile components removed under reduced pressure and solid added to a column and purified via column chromatography (Si02, 40% ethylacetate in hexane) to give 0.77 grams (86%) of Pyrimidine-4,6-dicarboxylic acid monomethyl ester compound (20). XH NMR (300 MHz, CD3OD) delta 4.04 (s, 3H), 8.59 (s, 1H), 9.46 (s, 1H). LC-MS (M+H) 183.
76%		To a solution of sodium hydroxide (1.00 g) in dry methanol (50 mL) was added commercially available <strong>[6345-43-3]pyrimidine-4,6-dicarboxylic acid dimethyl ester</strong> (4.91 g). The resulting suspension was stirred at room temperature for 1 h. Then a 4M solution of hydrochloric acid in dioxane (6.25 mL) was added and stirring at room temperature was continued for 10 min. The mixture was concentrated and purified by flash chromatography (silica, dichloromethane/methanol) to afford the title compound (3.48 g; 76%). [MH]+=183.

76%

Preparative Example 200; Step A; To a solution of sodium hydroxide (1.00 g) in dry methanol (50 mL) was added commercially available [6345-43-3]pyrimidine-4,6-dicarboxylic acid dimethyl ester (4.91 g). The resulting suspension was stirred at room temperature for 1 h. Then a 4M solution of hydrochloric acid in dioxane (6.25 mL) was added and stirring at room temperature was continued for 10 min. The mixture was concentrated and purified by flash chromatography (silica, dichloromethane/methanol) to afford the title compound (3.48 g; 76%). [MH]+=183.

References: [1]Patent: WO2019/99977,2019,A2 .Location in patent: Paragraph 00362; 00364.
[2]Patent: WO2014/62204,2014,A1 .Location in patent: Page/Page column 38.
[3]Patent: US2006/173183,2006,A1 .Location in patent: Page/Page column 125.
[4]Patent: US2007/155739,2007,A1 .Location in patent: Page/Page column 38.

12
[ 6345-43-3 ]
pyrimidine-4,6-dicarbohydrazide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
92%	With hydrazine hydrate; In ethanol; for 18h;Reflux;	General procedure: A solution of the corresponding dimethyl ester (10mmol) and hydrazine hydrate (10.9mL, 11.2g, 220mmol) in ethanol (150mL) was heated under reflux for 18h and then cooled to room temperature. The precipitate was filtered, washed twice with ethanol, once with ether, and dried, to give the bis(acylhydrazide) which was sufficiently pure and employed without further purification.
	With hydrazine hydrate; In methanol;	Example 14 Pyrimidine-4,6-dicarboxylic acid dihydrazide (formula I: R1 =--NH2; R2 =H) 2 g of <strong>[6345-43-3]dimethyl pyrimidine-4,6-dicarboxylate</strong> (prepared in accordance with the method of H. Yamada, Heterocycles, 13, 235 (1979)) are dissolved in 75 ml of methanol at room temperature. 1.1 g of hydrazine hydrate are added. A yellow precipitate is formed and is stirred for 3 hours and then filtered off with suction. Yield: 1.9 g; melting point:

References: [1]European Journal of Medicinal Chemistry,2019,vol. 178,p. 13 - 29.
[2]Patent: US5130317,1992,A .

13
[ 6345-43-3 ]
[ 27298-97-1 ]
C₁₅H₁₄BrN₃O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
61%	In N,N-dimethyl-formamide; at 70℃; for 72h;	Preparative Example 204; Step A; A solution of commercially available <strong>[6345-43-3]pyrimidine-4,6-dicarboxylic acid dimethyl ester</strong> (7.14 g) and commercially available (S)-1-(4-bromophenyl)ethylamine (5.06 g) in dry N,N-dimethylformamide (30 mL) was heated to 70 C. for 3 d. The solution was diluted with ethyl acetate and washed with 1N HCl, water and brine. Purification by flash filtered (silica, cyclohexane/ethyl acetate 7:3) afforded the intermediate (5.65 g; 61%) as a colourless oil. [MH]+=364/366.

References: [1]Patent: US2007/155739,2007,A1 .Location in patent: Page/Page column 39.

14
[ 6345-43-3 ]
[ 16490-02-1 ]

Yield	Reaction Conditions	Operation in experiment
86%		Pyrimidine-4,6-dicarboxylic acid (8a)To a solution of 11a (170 mg, 0.87 mmol) in MeOH (5 mL) was added IN NaOH (5 mL, 5.00 mmol). The solution was stirred for 2 hrs at room temperature. The solvent was then removed by evaporation and the concentrated solution acidified with 5N HCl to pH 2-3. The resultant white precipitate was collected by filtration and washed with H2O (2 mL) to yield 125 mg (86%) of 8a.

References: [1]Journal of Medicinal Chemistry,2008,vol. 51,p. 7053 - 7056.
[2]Patent: WO2010/43866,2010,A2 .Location in patent: Page/Page column 77.

15
[ 6345-43-3 ]
4,6-pyrimidinebis(carboxylic acid amide) [ No CAS ]

References: [1]Journal of the American Chemical Society,2013,vol. 135,p. 13298 - 13301.
[2]Chemical Communications,2010,vol. 46,p. 4755 - 4757.

16
[ 6345-43-3 ]
C₆H₂N₆S₄ [ No CAS ]

References: [1]Journal of the American Chemical Society,2013,vol. 135,p. 13298 - 13301.

17
[ 6345-43-3 ]
C₂₆H₆F₂₄Mn₂N₆O₈S₄ [ No CAS ]

References: [1]Journal of the American Chemical Society,2013,vol. 135,p. 13298 - 13301.

18
[ 6345-43-3 ]
[ 50844-89-8 ]

References: [1]Journal of the American Chemical Society,2013,vol. 135,p. 13298 - 13301.

19
[ 6345-43-3 ]
N4,N4,N4,N6,N6,N6-hexakis(trimethylsilyl)pyrimidine-4,6-dicarboxamidine [ No CAS ]

References: [1]Journal of the American Chemical Society,2013,vol. 135,p. 13298 - 13301.

20
[ 6345-43-3 ]
4,6-bis(1,2,3,5-dithiadiazolium)pyrimidine dichloride [ No CAS ]

References: [1]Journal of the American Chemical Society,2013,vol. 135,p. 13298 - 13301.

21
[ 6345-43-3 ]
[ 1605325-10-7 ]